Skip to main content

Advertisement

SpringerLink
Log in

New generation devices for transfemoral transcatheter aortic valve replacement are superior compared with last generation devices with respect to VARC-2 outcome

  • Original Article
  • Published:
Cardiovascular Intervention and Therapeutics Aims and scope Submit manuscript

Abstract

New generation devices for transcatheter aortic valve replacement have been optimized to improve clinical outcome. We compared procedural, in-hospital, 30 days and 12 months outcome of the new generation repositionable Boston Lotus Valve and the balloon-expandable Edwards Sapien 3 valve with the last generation self-expandable Medtronic CoreValve and the balloon-expandable Edwards Sapien XT. Between 2010 and 2015 consecutive patients treated with the Medtronic CoreValve (N = 100), Edwards Sapien XT (N = 100), Edwards Sapien S3 (N = 100) and Boston Lotus device (N = 100) were enrolled. There was no moderate or severe AR with the new generation devices as compared with 11.5% with last generation devices (p < 0.01). None or trace aortic regurgitation was lowest with the Lotus valve. Pacemaker implantation due to II° or III° atrioventricular block was comparable for the self-expandable CoreValve (21%) and the mechanically deployed Lotus Valve (23%) and lower for the Sapien 3 (15%) and XT valve (8%; p < 0.01). Early safety endpoint at 30 days (21 vs. 9%, p < 0.01), major vascular complications (12 vs. 2.5%, p < 0.01), all-cause mortality (9.5 vs. 2%, p < 0.01) and rate of disabling and non-disabling stroke (7.5 vs. 3.5%, p < 0.01) were significantly lower with the new generation devices. In multivariate analyses, valve type was an independent predictor for 30 days early safety endpoint and 12 months all-cause mortality. TAVR with the new generation Edwards Sapien 3 and Boston Lotus valves was associated with no moderate and severe aortic regurgitation, significantly lower major vascular complications and a significant improvement in 30 days and 12 months outcome.

Clinicaltrials.gov NCT02162069.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Thourani VH, Kodali S, Makkar RR, Herrmann HC, Williams M, Babaliaros V, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet. 2016;387(10034):2218–25.

    Article  PubMed  Google Scholar 

  2. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374(17):1609–20.

    Article  PubMed  CAS  Google Scholar 

  3. Kodali S, Pibarot P, Douglas PS, Williams M, Xu K, Thourani V, et al. Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. Eur Heart J. 2015;36(7):449–56.

    Article  PubMed  Google Scholar 

  4. Abdel-Wahab M, Mehilli J, Frerker C, Neumann FJ, Kurz T, Tölg R, et al. Comparison of balloon-expandable vs self-expandable valves in patients undergoing transcatheter aortic valve replacement: the CHOICE randomized clinical trial. JAMA. 2014;311(15):1503–14.

    Article  PubMed  CAS  Google Scholar 

  5. Daneault B, Koss E, Hahn RT, Kodali S, Williams MR, Généreux P, et al. Efficacy and safety of postdilatation to reduce paravalvular regurgitation during balloon-expandable transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2013;6(1):85–91.

    Article  PubMed  Google Scholar 

  6. Généreux P, Webb JG, Svensson LG, Kodali SK, Satler LF, Fearon WF, et al. Vascular complications after transcatheter aortic valve replacement: insights from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial. J Am Coll Cardiol. 2012;60(12):1043–52.

    Article  PubMed  Google Scholar 

  7. Achenbach S, Delgado V, Hausleiter J, Schoenhagen P, Min JK, Leipsic JA. SCCT expert consensus document on computed tomography imaging before transcatheter aortic valve implantation (TAVR)/transcatheter aortic valve replacement (TAVR). J Cardiovasc Comput Tomogr. 2012;6(6):366–80.

    Article  PubMed  Google Scholar 

  8. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med. 2000;343(9):611–7.

    Article  PubMed  CAS  Google Scholar 

  9. Wöhrle J, Gonska B, Rodewald C, Seeger J, Scharnbeck D, Rottbauer W. Transfemoral aortic valve implantation with the New Edwards Sapien 3 valve for treatment of severe aortic stenosis-impact of valve size in a single center experience. PLoS One. 2016;11(3):e0151247.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Wöhrle J, Gonska B, Rodewald C, Trepte U, Koch S, Scharnbeck D, et al. Transfemoral aortic valve implantation with the repositionable Lotus valve compared with the balloon-expandable Edwards Sapien 3 valve. Int J Cardiol. 2015;195:171–5.

    Article  PubMed  Google Scholar 

  11. Seeger J, Gonska B, Rodewald C, Rottbauer W, Wöhrle J. Bicuspid aortic stenosis treated with the repositionable and retrievable Lotus Valve. Can J Cardiol. 2016;32(1):135.

    Article  PubMed  Google Scholar 

  12. Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol. 2012;60(15):1438–54.

    Article  PubMed  Google Scholar 

  13. Sellers RD, Levy MJ, Amplatz K, Lillehei CW. Left retrograde cardioangiography in acquired cardiac disease: technic, indications and interpretation in 700 cases. Am J Cardiol. 1964;14:437–47.

    Article  PubMed  CAS  Google Scholar 

  14. Tarantini G, Mojoli M, Windecker S, Wendler O, Lefèvre T, Saia F, et al. Prevalence and impact of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the SOURCE XT Prospective Multicenter Registry. JACC Cardiovasc Interv. 2016;9(9):937–46.

    Article  PubMed  Google Scholar 

  15. Amat-Santos IJ, Dahou A, Webb J, Dvir D, Dumesnil JG, Allende R, et al. Comparison of hemodynamic performance of the balloon-expandable SAPIEN 3 versus SAPIEN XT transcatheter valve. Am J Cardiol. 2014;114(7):1075–82.

    Article  PubMed  Google Scholar 

  16. Webb J, Gerosa G, Lefèvre T, Leipsic J, Spence M, Thomas M, et al. Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve. J Am Coll Cardiol. 2014;64(21):2235–43.

    Article  PubMed  Google Scholar 

  17. Athappan G, Patvardhan E, Tuzcu EM, Svensson LG, Lemos PA, Fraccaro C, et al. Incidence, predictors, and outcomes of aortic regurgitation after transcatheter aortic valve replacement: meta-analysis and systematic review of literature. J Am Coll Cardiol. 2013;61(15):1585–95.

    Article  PubMed  Google Scholar 

  18. Husser O, Pellegrini C, Kessler T, Burgdorf C, Thaller H, Mayr NP, et al. Outcomes after transcatheter aortic valve replacement using a novel balloon-expandable transcatheter heart valve: a single-center experience. JACC Cardiovasc Interv. 2015;8(14):1809–16.

    Article  PubMed  Google Scholar 

  19. Meredith Am IT, Walters DL, Dumonteil N, Worthley SG, Tchétché D, Manoharan G, et al. Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system: 30-day primary endpoint results from the REPRISE II study. J Am Coll Cardiol. 2014;64(13):1339–48.

    Article  PubMed  Google Scholar 

  20. Van Mieghem NM, Schipper ME, Ladich E, Faqiri E, van der Boon R, Randjgari A, et al. Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation. 2013;127(22):2194–201.

    Article  PubMed  Google Scholar 

  21. Lansky AJ, Schofer J, Tchetche D, Stella P, Pietras CG, Parise H, et al. A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial. Eur Heart J. 2015;36(31):2070–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine II, Cardiology, University of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany

    Julia Seeger, Birgid Gonska, Wolfgang Rottbauer & Jochen Wöhrle

Authors
  1. Julia Seeger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Birgid Gonska
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wolfgang Rottbauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jochen Wöhrle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jochen Wöhrle.

Ethics declarations

Conflict of interest

Supported by an unrestricted research grant from Boston Scientific.

Funding

None.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 18 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seeger, J., Gonska, B., Rottbauer, W. et al. New generation devices for transfemoral transcatheter aortic valve replacement are superior compared with last generation devices with respect to VARC-2 outcome. Cardiovasc Interv and Ther 33, 247–255 (2018). https://doi.org/10.1007/s12928-017-0477-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12928-017-0477-6

Keywords

Search

Navigation